350 related articles for article (PubMed ID: 19134028)
1. Prevention of arthropathy in haemophilia: prophylaxis.
Santagostino E; Mancuso ME
Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis in people with haemophilia.
Coppola A; Franchini M; Tagliaferri A
Thromb Haemost; 2009 Apr; 101(4):674-81. PubMed ID: 19350110
[TBL] [Abstract][Full Text] [Related]
3. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
Mancuso ME; Graca L; Auerswald G; Santagostino E
Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
[TBL] [Abstract][Full Text] [Related]
4. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
Manco-Johnson M
Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
[TBL] [Abstract][Full Text] [Related]
5. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis in adults with haemophilia.
Hay CR
Haemophilia; 2007 Sep; 13 Suppl 2():10-5. PubMed ID: 17685918
[TBL] [Abstract][Full Text] [Related]
9. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
Berntorp E
Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
[TBL] [Abstract][Full Text] [Related]
10. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
11. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
12. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States.
Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C
Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of haemophilic synovitis: clinical aspects.
Hoots WK; Rodriguez N; Boggio L; Valentino LA
Haemophilia; 2007 Nov; 13 Suppl 3():4-9. PubMed ID: 17822514
[TBL] [Abstract][Full Text] [Related]
14. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
[TBL] [Abstract][Full Text] [Related]
15. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
Taki M; Shirahata A
Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
[TBL] [Abstract][Full Text] [Related]
16. Prevention of haemophilic synovitis: prophylaxis.
Lee CA
Haemophilia; 2007 Nov; 13 Suppl 3():20-5. PubMed ID: 17822517
[TBL] [Abstract][Full Text] [Related]
17. Identifying and overcoming barriers to prophylaxis in the management of haemophilia.
Petrini P
Haemophilia; 2007 Sep; 13 Suppl 2():16-22. PubMed ID: 17685919
[TBL] [Abstract][Full Text] [Related]
18. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
[TBL] [Abstract][Full Text] [Related]
19. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series.
Valentino LA
Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.
Mancuso ME; Mannucci PM; Sartori A; Agliardi A; Santagostino E
Br J Haematol; 2008 May; 141(5):689-95. PubMed ID: 18410458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
